Researcher discovers new predictor of prostate cancer recurrence

In order to make this discovery, researchers examined prostate cancer tissue samples that had been removed during surgical procedures on cancer patients. The researchers found that men whose tumors showed a silencing of the gene CDH13 had a five-fold increased risk of prostate cancer recurrence compared with men whose tumors showed no silencing of this gene, according to Joshi Alumkal, M.D., OHSU Cancer Institute member and assistant professor of medicine, (hematology/medical oncology), OHSU School of Medicine. In normal cells, this gene is active, but in some cancer cells it may be turned off, which leads to a propensity for metastasis, or spreading.

The research, “DNA Methylation as a Predictor of Prostate Cancer Recurrence,” will be presented as a poster on Thursday, Feb. 14 at the 2008 American Society of Clinical Oncology Genitourinary Symposium in San Francisco.

In this study, the largest of its kind examining DNA methylation changes and prostate cancer recurrence, the research team looked at tissue samples from 151 research subjects with localized prostate cancer with at least five years of follow-up after their prostatectomies. During prostate cancer formation, the DNA may be modified through a process called DNA methylation, which turns off many important genes called tumor suppressor genes that act as the brakes on cancer cell growth or cancer cell spread. CDH13 is a prime example of one of these genes.

Two-thirds of the subjects were free of recurrence; one-third had a recurrence.

“In the clinic, those of us who care for patients with prostate cancer look at the pathology report and PSA blood test to determine how a patient will do after surgery and how aggressive their tumors might be. However, these tools are not perfect. We were searching for a biomarker to identify patients for whom these clinical predictors currently mis-classify as being at low risk for recurrence. Finding such a predictor would improve upon our existing tools and would allow us to make more accurate predictions about tumor behavior down the road,” Alumkal said. “Given that there were approximately 218,890 new cases of prostate cancer diagnosed in 2007 and 27,050 deaths, this work may have far-reaching implications.”

Before this finding can be incorporated into routine clinical practice, it must be confirmed in a separate, larger group of patients.

Source: Oregon Health & Science University

PSA screening may be biased against obese men, leading to more aggressive cancers
Testing men for elevated levels of prostate-specific antigen (PSA) in the blood -- the gold standard screening test for prostate cancer -- may be biased against obese men, whose PSA levels tend to be deceptively low. And this bias may be creating more aggressive cancers in this population by delaying diagnosis, according to a new study led by investigators in the Duke Prostate Center and the Durham Veterans Affairs (VA) Medical Center.
Researchers locate and image prostate cancer as it spreads to lymph nodes
Using an engineered common cold virus, UCLA researchers delivered a genetic payload to prostate cancer cells that allowed them, using Positron Emission Tomography (PET), to locate the diseased cells as they spread to the lymph nodes, the first place prostate cancer goes before invading other organs.
Elevated biomarkers predict risk for prostate cancer recurrence
A simple blood test screening for a panel of biomarkers can accurately predict whether a patient who has had prostate cancer surgery will have a recurrence or spread of the disease.
Radiation therapy prolongs life in men with recurrent prostate cancer
Men whose tumors recur after prostate cancer surgery are three times more likely to survive their disease long term if they undergo radiotherapy within two years of the recurrence. Surprisingly, survival benefits were best in men whose new tumors were growing fastest, according to results of a "look-back" study of 635 men by Johns Hopkins Medical Institutions researchers reported June 18 in the Journal of the American Medical Association.
Outing the outliers: Strategy matches oncogene with subtype of prostate cancer
A new study reveals a previously unidentified candidate oncogene that appears to play a significant role in a subset of prostate cancers. The research, published by Cell Press in the June issue of the journal Cancer Cell, describes a new strategy that can be used to find "outlier" genes in cancer subtypes that are not well understood.
Researchers discover traits of aggressive form of prostate cancer
Researchers led by a team at the Michigan Center for Translational Pathology at the University of Michigan Health System have identified traits of an aggressive type of prostate cancer that occurs in about 10 percent of men who have the disease. They hope the discovery could lead, possibly within the next few years, to a simple urine test that will help to diagnose this variation of prostate cancer.
Cancer survivors have low levels of physical activity and high levels of obesity
A new study reveals that many cancer survivors are inactive and obese, which may negatively affect the control of their disease. The findings, which come from a study of cancer survivors in Canada, show that a cancer diagnosis does not appear to prompt significant behavior change and that interventions to increase physical activity and promote better eating habits among cancer survivors are warranted. The study is published in the June 1, 2008 issue of CANCER, a peer-reviewed journal of the American Cancer Society.
MRI findings help forecast prostate cancer prognosis
Magnetic resonance imaging (MRI) findings in patients about to undergo radiation therapy for prostate cancer can help predict the likelihood that the cancer will return and spread post-treatment, according to a new study published in the April issue of the journal Radiology.

Researcher discovers new predictor of prostate cancer recurrence

Related stories:

News discussion: